Last10K.com

Amyris, Inc. (AMRS) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

AMRS Annual Reports

Amyris, Inc.

CIK: 1365916 Ticker: AMRS
FOR IMMEDIATE RELEASE AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS • 2021 full year total revenue grew 97% year-over-year to $342 million • Q4 and full year 2021 consumer revenue +86% and +78% respectively versus prior year • Accelerating consumer growth and new partnerships expected to double core revenue in 2022 Emeryville, CA – March 1, 2022 – Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021. “Accelerating growth of our consumer brands resulted in record levels for our consumer and core revenue,” said John Melo, President and Chief Executive Officer. “Biossance and Pipette, together with better than expected performance of our recently launched clean beauty brands, JVN and Rose Inc., contributed to strong consumer revenue. We now have established offerings in skincare, hair, mother and baby, and color cosmetics, and we expect to continue to expand our offering throughout 2022 with menopause and Gen-Z beauty brands. Our brands are loved by consumers and offer high quality, science backed solutions that allow consumers to choose sustainable products without compromising product performance.” “We made substantial progress in the construction of our fermentation plant in Barra Bonita, Brazil which we expect to be operational in the second quarter of 2022. Additionally, we continue to expand and integrate our consumer supply chain. We expect both our Brazil plant and consumer production consolidation to help us meet the growing demand for sustainable alternatives to existing chemistry. As the year progresses, we expect these investments to notably improve our gross margin, reduce our operating expenses and provide greater flexibility in meeting our production targets.” “We completed joint ventures with ImmunityBio and Minerva Foods demonstrating the power of our Lab-to- Market technology capabilities. Everyone in our organization has worked tirelessly to position us for success. As a result of these efforts, based on 2021 exit rates, strong 2022 consumer performance to date and future plans, we estimate 2022 total revenue to be approximately double 2021 core revenue.” Business and Operational Highlights In line with the evolution of Amyris’ business model we are now reporting core revenue which comprises consumer and technology access revenue. Technology access includes ingredient product revenue, R&D collaboration, and technology licenses. Core revenue excludes strategic transactions and other one-off items. Consumer • Record consumer revenue of $32.2 million increased 86% versus Q4 2020. Consumer revenue comprised record revenue from the Company’s three legacy brands, Biossance, Pipette, and Purecane, and strong early-stage performance of brands introduced during H2 of 2021, particularly Rose, Inc. and JVN. • 53% of Q4 2021 consumer revenue originated from direct-to-consumer (DTC) selling via the brands ecommerce platforms, and 47% from retail, with a combination of in-store and online sales. This compares to 59% DTC in Q4 of 2020. This shift is a result of more stores being closed at this time last year due to COVID-19, our further expansion into specialty and mass retail and a change in brand mix. • Pipette Q4 2021 record revenue nearly doubled when compared to the prior year quarter and we are preparing to launch Pipette in Walgreens in 2022. In Q4 2021, Olika, shipped its first products for sale in


The following information was filed by Amyris, Inc. (AMRS) on Tuesday, March 1, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Amyris, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amyris, Inc..

Continue

Assess how Amyris, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amyris, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Geography
Product
Expense
Debt
Cash Flow
Other
Inside Amyris, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Consolidated Statements Of Stockholders' Deficit And Mezzanine Equity
Consolidated Statements Of Stockholders' Deficit And Mezzanine Equity (Parenthetical)
Acquisitions
Acquisitions (Tables)
Acquisitions - Beauty Labs Allocation (Details)
Acquisitions - Beauty Labs Narrative (Details)
Acquisitions - Costa Brazil Allocation (Details)
Acquisitions - Costa Brazil Narrative (Details)
Acquisitions - Costa Brazil Purchase Consideration (Details)
Acquisitions - Mg Empower Allocation (Details)
Acquisitions - Mg Empower Narrative (Details)
Acquisitions - Olika Allocation (Details)
Acquisitions - Olika Narrative (Details)
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Accrued And Other Current Liabilities (Details)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Allowance For Doubtful Accounts (Details)
Balance Sheet Details - Deferred Cost Of Product Sold (Details)
Balance Sheet Details - Depreciation And Amortization (Details)
Balance Sheet Details - Goodwill (Details)
Balance Sheet Details - Intangible Assets (Details)
Balance Sheet Details - Inventories (Details)
Balance Sheet Details - Maturities Of Financing And Operating Leases (Details)
Balance Sheet Details - Other Assets (Details)
Balance Sheet Details - Other Noncurrent Liabilities (Details)
Balance Sheet Details - Prepaid Expenses And Other Current Assets (Details)
Balance Sheet Details - Property, Plant And Equipment (Details)
Balance Sheet Details - Right-Of-Use Assets And Related Lease Liabilities (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Concentration Of Credit Risk (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Consolidated Variable-Interest Entities And Unconsolidated Investments
Consolidated Variable-Interest Entities And Unconsolidated Investments (Tables)
Consolidated Variable-Interest Entities And Unconsolidated Investments - Assets And Liabilities (Details)
Consolidated Variable-Interest Entities And Unconsolidated Investments - Equity Method Investment (Details)
Consolidated Variable-Interest Entities And Unconsolidated Investments - Narrative (Details)
Consolidated Variable-Interest Entities And Unconsolidated Investments - Noncontrolling Interest (Details)
Debt
Debt (Tables)
Debt - 2026 Convertible Senior Notes (Details)
Debt - 2026 Convertible Senior Notes, Schedule Of Convertible Debt Components (Details)
Debt - 2026 Senior Convertible Notes, Schedule Of Interest Expense (Details)
Debt - Amendment No. 1 To Foris Lsa ??? Foris, Related Party (Details)
Debt - Amendment To Senior Convertible Notes (Details)
Debt - Debt Components (Details)
Debt - Dsm $25 Million Note (Details)
Debt - Dsm $8 Million Note (Details)
Debt - Exchange Of Senior Convertible Notes Due 2022 (Details)
Debt - Foris $5 Million Note ??? Foris, Related Party (Details)
Debt - Ginkgo Note, Partnership Agreement And Note Amendment (Details)
Debt - Letters Of Credit (Details)
Debt - Long-Term Debt Instruments (Details)
Debt - Naxyris Lsa As Amendment (Details)
Debt - Nikko Notes (Details)
Debt - Schedule Of Debt Extinguishments (Details)
Debt - Schottenfeld Notes (Details)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Acquisition Related Contingent Consideration Consideration Roll Forward (Details)
Fair Value Measurement - Acquisition Related Contingent Consideration Narrative (Details)
Fair Value Measurement - Bifurcated Embedded Features In Debt Instruments (Details)
Fair Value Measurement - Fair Value Of Debt ??? Foris Convertible Note (Lsa Amendment) (Details)
Fair Value Measurement - Fair Value, Assets, And Liabilities Measured On Recurring Basis (Details)
Fair Value Measurement - Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation (Details)
Fair Value Measurement - Financial Assets And Liabilities (Details)
Fair Value Measurement - Freestanding Derivative Instruments (Details)
Fair Value Measurement - Input Assumptions (Details)
Fair Value Measurement - Market Based Assumptions (Details)
Fair Value Measurement - Reconciliation For Compound Embedded Derivative Liability (Details)
Geographical Information
Geographical Information (Details)
Geographical Information (Tables)
Income Taxes
Income Taxes (Tables)
Income Taxes - Activity In The Deferred Tax Assets Valuation Allowance (Details)
Income Taxes - Additional Information (Details)
Income Taxes - Components Of Benefit (Provision) (Details)
Income Taxes - Components Of Income Loss (Details)
Income Taxes - Deferred Tax Assets And Liabilities (Details)
Income Taxes - Effective Tax Rate Reconciliation (Details)
Income Taxes - Uncertain Tax Benefits (Details)
Mezzanine Equity
Mezzanine Equity - Gates Foundation (Details)
Mezzanine Equity - Ingredion Contingently Redeemable Noncontrolling Interest In Subsidiary (Details)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (Tables)
Net Loss Per Share Attributable To Common Stockholders - Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Net Loss Per Share Attributable To Common Stockholders - Calculation Of Basic And Diluted Net Loss Per Share Of Common Stock (Details)
Related Party Transactions
Related Party Transactions (Tables)
Related Party Transactions - Related Party Accounts Payable (Details)
Related Party Transactions - Related Party Accounts Receivable (Details)
Related Party Transactions - Related Party Revenues (Details)
Related Party Transactions - Schedule Of Related Party Debt (Details)
Revenue Recognition
Revenue Recognition (Tables)
Revenue Recognition - Accessbio Llc Jv License (Details)
Revenue Recognition - Amf Low Carbon Llc License Agreement (Details)
Revenue Recognition - Contract Balances (Details)
Revenue Recognition - Disaggregation Of Revenue (Details)
Revenue Recognition - Dsm Developer License (Details)
Revenue Recognition - Dsm Ingredients Collaboration (Details)
Revenue Recognition - Dsm License Agreement And Contract Asset (Details)
Revenue Recognition - Dsm Performance Agreement (Details)
Revenue Recognition - Purecircle License And Supply Agreement (Details)
Revenue Recognition - Remaining Performance Obligations (Details)
Revenue Recognition - Revenue In Connection With Significant Revenue Agreement (Details)
Revenue Recognition - Yifan Agreement (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 2010 Employee Stock Purchase Plan (Details)
Stock-Based Compensation - 2020 Equity Incentive Plans (Details)
Stock-Based Compensation - Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs (Details)
Stock-Based Compensation - Espp Activity And Expense (Details)
Stock-Based Compensation - Evergreen Shares For 2020 Equity Incentive Plan And 2010 Employee Stock Purchase Plan (Details)
Stock-Based Compensation - Options Activity (Details)
Stock-Based Compensation - Performance-Based Stock Units (Details)
Stock-Based Compensation - Restricted Stock Units (Including Performance-Based Stock Units) Activity And Expense (Details)
Stock-Based Compensation - Share-Based Compensation, Stock Options And Stock Appreciation Rights Award Activity (Details)
Stock-Based Compensation - Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)
Stock-Based Compensation - Temporal Display Of Share-Based Compensation, Restricted Stock And Restricted Stock Units Activity (Details)
Stockholders??? Equity (Deficit)
Stockholders??? Equity (Deficit) (Tables)
Stockholders??? Equity (Deficit) - Call Options Related To 2026 Convertible Senior Notes (Details)
Stockholders??? Equity (Deficit) - Increase In Authorized Common Stock (Details)
Stockholders??? Equity (Deficit) - Number Of Callable Shares (Details)
Stockholders??? Equity (Deficit) - Primary Offering (Details)
Stockholders??? Equity (Deficit) - Warrant Activity (Details)
Stockholders??? Equity (Deficit) - Warrant Exercises (Details)
Subsequent Events
Subsequent Events (Details)
Ticker: AMRS
CIK: 1365916
Form Type: 10-K Annual Report
Accession Number: 0001365916-22-000032
Submitted to the SEC: Wed Mar 09 2022 6:19:29 AM EST
Accepted by the SEC: Wed Mar 09 2022
Period: Friday, December 31, 2021
Industry: Industrial Organic Chemicals

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amrs/0001365916-22-000032.htm